This post was originally published on this site The Phase 1 trial evaluating Betalutin — an investigational tumor-targeting antibody labeled with a type of radiation — in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is now fully enrolled, its developer, Nordic Nanovector, announced. The ongoing LYMRIT 37-05 trial (NCT02658968) includes 18 patients who are…
This post was originally published on this site A new chimeric antigen receptor (CAR) T-cell therapy derived from induced pluripotent stem cells (iPSCs) has been transferred to Takeda from the Center for iPS Cell Research and Application (CiRA) at Kyoto University to prepare for clinical testing. Under the terms of the collaboration, Takeda shall retain the…
This post was originally published on this site Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 clinical trial shows. It also improved several other patient outcomes, extending the time to a new cancer…
This post was originally published on this site A $566,000 grant, awarded via the Ovarian Cancer Research Foundation, will support research in Australia that aims to establish the use of contraceptive pills as an effective strategy for preventing ovarian cancer. The three-year grant will enable researchers to continue exploring how changes in female reproductive hormones…
This post was originally published on this site A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial is recruiting people with advanced disease, who received at least three prior lines of therapy. The open-label study (NCT03933735) will first test increasing…
This post was originally published on this site Lotus Pharmaceuticals has launched the first generic version of Pierre Fabre’s Navelbine (vinorelbine) in soft capsule form in Europe for the treatment of advanced breast cancer and advanced non-small-cell lung cancer, the company has announced. Vinorelbine soft capsules are now being marketed across Europe, including in France,…
This post was originally published on this site The Gray Foundation awarded a $3.75 million grant to a researcher team to study how BRCA1 or BRCA2 mutations, along with other genetic anomalies, increase the risk of breast, ovarian, and other cancers. The “team science grant” will fund the research for four years. The project is…
This post was originally published on this site A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side effect of immunomodulatory therapies (IMiD) for multiple myeloma. Researchers established the set of factors — based on a person’s age, race, and medical…
This post was originally published on this site Oklahoma suffers more tornadoes than any other state, has the highest per-capita rate of women in U.S. prisons, ranks second in the number of teen births per 100,000 teenage girls, and has the nation’s third-highest rate of uninsured residents — with 13.9% of all Oklahomans lacking health…
This post was originally published on this site Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come…
